ALLO — Allogene Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $618.97m
- $174.34m
- $0.10m
- 22
- 13
- 52
- 19
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -185 | -250 | -257 | -333 | -327 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 49.4 | 73.6 | 93.8 | 94.1 | 90.6 |
Unusual Items | |||||
Purchased R&D | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -7.21 | 53.9 | -32.1 | 3.71 | -15.3 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -137 | -115 | -185 | -221 | -238 |
Capital Expenditures | -50.8 | -66 | -21.4 | -5.19 | -1.52 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 215 | -439 | 185 | 111 | 165 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 164 | -505 | 164 | 106 | 163 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 59 | 634 | 12 | 2.95 | 95.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 85.7 | 13.4 | -9.19 | -111 | 21.3 |